Alendronate Sodium
Product Images NDC 50090-2322

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 50090-2322). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Alendronate Fig1)

A line graph showing the cumulative incidence (%) of hip fractures over 36 months in a three-year study comparing Alendronate Sodium to placebo in patients with baseline radiographic vertebral fractures. The graph depicts lower incidence for Alendronate Sodium versus placebo over time.*

FDA Label Image

Figure 2 (Alendronate Fig2)

A bar chart depicting osteoporosis treatment studies in postmenopausal women showing the mean percentage increase in bone mineral density (BMD) at the lumbar spine, femoral neck, and trochanter over three years with Alendronate 10 mg/day. The chart compares results from U.S. and multinational studies, displaying higher BMD percentage increases in the lumbar spine and trochanter for U.S. studies compared to multinational studies.*

FDA Label Image

Figure 3 (Alendronate Fig3)

This image presents two line graphs comparing the time course effect of Alendronate 10 mg/day versus placebo on lumbar spine bone mineral density (BMD) percent change from baseline in postmenopausal women with osteoporosis. The left graph shows data from a U.S. study and the right graph from a multinational study, with BMD percent change on the y-axis over a 36-month period on the x-axis.*

FDA Label Image

Figure 4 (Alendronate Fig4)

Two bar graphs titled 'Osteoporosis Prevention Studies in Postmenopausal Women' compare mean percent change in bone mineral density (BMD) from baseline over 2-year and 3-year studies. Bars represent BMD changes at lumbar spine, femoral neck, trochanter, and total body for Alendronate 5 mg/day versus placebo groups, showing positive changes with Alendronate and negative or lower changes with placebo.*

FDA Label Image

Figure 5 (Alendronate Fig5)

A bar chart depicting the increase in bone mineral density (BMD) as a mean percentage increase relative to placebo after one year of Alendronate 5 mg/day treatment in glucocorticoid-treated patients. The BMD increase is shown for three anatomical sites: Lumbar Spine, Femoral Neck, and Trochanter, comparing U.S. and Multinational study groups with error bars representing standard error.*

FDA Label Image

Figure 6 (Alendronate Fig6)

A line graph titled 'Studies in Paget's Disease of Bone' showing the effect on serum alkaline phosphatase levels over 6 months. It compares Alendronate 40 mg/day (two studies) and Etidronate 400 mg/day against placebo. The vertical axis represents mean percent change from baseline in serum alkaline phosphatase (± SE), and the horizontal axis is time in months. Data points show a greater decrease in serum alkaline phosphatase for Alendronate groups compared to Etidronate and placebo.*

FDA Label Image

Chemical Structure (Alendronate Str)

Chemical structure diagram of Alendronate Sodium showing the molecular composition and arrangement including amino, hydroxyl, phosphonate groups, and sodium hydrate components as depicted in the image.*

FDA Label Image

Label Image (Lbl500902322)

Label for Alendronate Sodium 70 mg tablets, distributed by A-S Medication Solutions. The label includes storage instructions to store at 68-77 degrees Fahrenheit and notes that the package contains 4 tablets. It also provides manufacturer and distributor information and has a QR code on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.